-- Health insurer group asks Gilead to cut hepatitis C drug price
-- By Michele Gershberg
-- Wed Jul 23, 2014 04:54PM EDT
-- None



July 23 (Reuters) - A prominent U.S. health insurer trade group on Wednesday called on Gilead Sciences Inc <GILD.> to lower the cost of its hepatitis C drug Sovaldi after the drugmaker reported nearly $3.5 billion in sales for the treatment in its second quarter.

